AzTrials
AzTrials

Resectable Hepatocellular CarcinomaPhase 2ASPIRENCT07018947

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

A Phase 2 study testing Atezolizumab and Bevacizumab in people with Resectable Hepatocellular Carcinoma, run by Fundacion Clinic per a la Recerca Biomédica at 12 sites in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Resectable Hepatocellular Carcinoma
What is being tested?
Atezolizumab and Bevacizumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
12 sitesSpain
Study dates
2 Jun 2026to Jun 2031
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed Informed Consent Form.
  • Age ≥ 18 years at the time of signing Informed Consent Form.
  • Ability to fully comply with the protocol, in the investigator's judgment.
  • Diagnosis of HCC confirmed by histology.
  • HCC that is amenable to R0 surgical resection with curative intent in the opinion of the surgeons and oncologists or hepatologists involved in the care of the participant.
  • HCC at high-risk of recurrence defined by either multifocality, large tumor diameter (>5cm), AFP (alpha-fetoprotein) ≥400ng/mL, poor tumor differentiation, or the presence of microvascular invasion.
Show all 32Show fewer
  • For patients with tumors between 3-5 cm, a predefined nomogram will be applied, indicating a high prevalence of microvascular invasion with a score >200 points. (Lie et al., 2016).
  • Measurable disease (at least one target lesion) according to RECIST v1.1 as determined by the investigator.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0.
  • Child-Pugh Class A.
  • No evidence of clinically significant portal hypertension (CSPH) or minor CSPH (HVPG <12 mmHg) in candidates for minor resection (fewer than 3 segments). (Galle et al., 2018) Clinically significant portal hypertension (CSPH) can be defined either by its gold standard measurement, a hepatic venous pressure gradient (HVPG) ≥10 mmHg, or by the presence of surrogate markers such as a platelet count <100,000 × 10³/µL combined with splenomegaly.
  • Willing to undergo a tumor biopsy at screening visit.
  • Baseline tumor tissue samples will be collected from all participants by means of a core-needle biopsy performed at study entry. A minimum of two core-needle biopsies are required. If a fresh biopsy is not deemed feasible by the investigator, archival tumor tissue may be submitted, provided the tissue was obtained from a biopsy performed within 3 months prior to enrollment and the patient has not received any anti-cancer therapy, including locoregional liver-directed therapy, since the time of the biopsy. Tumor and normal adjacent tissue specimen will be collected at surgery as fresh snap-frozen and formalin-fixed, paraffin-embedded (FFPE) format. FFPE tissue blocks are preferred, or a minimum of 20 slides must be submitted.
  • No prior locoregional or systemic treatment for HCC.
  • Adequate hematologic and end-organ function, defined by the following laboratory test results:
  • ANC ≥ 1.5 × 109/L (1500/µL) without granulocyte colony-stimulating factor (G-CSF) support.
  • Lymphocyte count ≥ 0.5 × 109/L (500/µL).
  • Platelet count ≥ 75 × 109/L (75,000/µL) without transfusion.
  • Hemoglobin ≥ 90 g/L (9.0 g/dL) without transfusion. Participants must not have required transfusion during screening or within 2 weeks prior to screening to meet this criterion.
  • AST, ALT, and ALP ≤ 5 × upper limit of normal (ULN).
  • Bilirubin ≤ 3 × ULN.
  • Adequate renal function: creatinine clearance by estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease Study (MDRD) formula ≥ 50 mL/min. Participants with creatinine clearance by estimating eGFR by MDRD formula of ≥ 30 mL/min and ≤ 50 mL/min may be enrolled if renal function was stable for ≥ 28 days prior to randomization.
  • Albumin ≥ 28 g/L (2.8 g/dL) without transfusion.
  • For participants not receiving anticoagulation: INR or aPTT ≤ 1.5 × ULN.
  • Documented virology status of hepatitis, as confirmed by screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV):
  • Patients with active HBV must have HBV DNA < 500 IU/mL during screening, must have initiated anti-HBV treatment at least 14 days prior treatment initiation, and must be willing to continue anti-HBV treatment during the study (per local standard of care, e.g., entecavir).
  • Patients with HCV, either with resolved infection (as evidenced by detectable antibody) or chronic infection (as evidenced by detectable HCV RNA), are eligible.
  • For patients with detectable HCV RNA and for whom HCV treatment is considered appropriate by the investigator, treatment should begin no sooner than 6 months following liver resection consistent with AASLD guidelines.
  • Negative HIV test at screening with the following exception:
  • Individuals with a positive HIV test at screening are eligible if they are stable on anti-retroviral therapy, have a CD4 count ≥ 200/mL, and have an undetectable viral load.
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm.

Who cannot join

  • Presence of extrahepatic disease or macrovascular invasion.
  • Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC, or other rare variants of HCC.
  • History of hepatic encephalopathy if clinically significant within one year prior to screening.
  • CSPH in candidates for major resection (more than 3 segments).
  • Moderate or severe ascites.
  • Active co-infection with HBV and HCV (defined as detectable HCV RNA plus positive HBV surface antigen or HBV DNA). Patients with a history of HCV infection but who are negative for HCV RNA by Polymerase Chain Reaction (PCR) will be considered non-infected with HCV.
Show all 59Show fewer
  • Known active co-infection with HBV and hepatitis D viral infection (HDV).
  • Prior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies.
  • Treatment with investigational therapy within 28 days prior to screening.
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding. Participants must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Participants who have undergone an EGD within 6 months prior screening do not need to repeat the procedure.
  • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to screening.
  • Inadequately controlled hypertension, defined as systolic blood pressure (BP) > 150 mmHg and/or diastolic BP > 100 mmHg (average of at least three readings at two or more sessions).
  • Anti-hypertensive therapy to achieve these parameters is allowed.
  • History of hypertensive crisis or hypertensive encephalopathy.
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to screening.
  • History of hemoptysis (≥ 2.5 mL of bright red blood per episode) within 1 month prior to screening.
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
  • Current or recent (≤ 10 days prior to screening) use of aspirin (> 325 mg/day) or treatment with clopidogrel, dipyramidole, ticlopidine, or cilostazol.
  • Chronic use of low dose aspirin (< 325 mg/day) for cardioprotection is allowed.
  • Current or recent (≤ 10 days prior to screening) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose.
  • Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR < 1.5 × ULN and aPTT is within normal limits within 14 days prior to screening.
  • Prophylactic use of low-molecular-weight heparin (LMWH; i.e., enoxaparin 40 mg/day) is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) are not recommended due to potential bleeding risk. Benefits and risks should be assessed, and caution exercised for use of direct oral anticoagulants.
  • The investigator should consider switching to other approved anticoagulants due to the risk of upper GI (gastrointestinal) bleeding in patients with HCC.
  • For prophylactic use of anticoagulants or thrombolytic therapies, the approved dose as described on the local label may be used.
  • History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to screening.
  • History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction, including subocclusive or occlusive syndrome related to the underlying disease, or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding prior to screening.
  • Evidence of abdominal free air that is not explained by paracentesis or recent (< 3 months) abdominal surgical procedure.
  • Serious, non-healing, or dehiscing wound, active ulcer, or untreated bone fracture.
  • Grade ≥ 2 proteinuria, as demonstrated by ≥ 2+ protein on dipstick urinalysis and ≥ 1.0 g of protein in a 24-hour urine collection.
  • All patients with ≥ 2+ protein on dipstick urinalysis at screening must undergo a 24-hour urine collection (or an alternative method such as protein/creatinine ratio, per local guidance) for protein and must demonstrate < 1 g of protein in 24 hours.
  • Patients with < 2+ protein on dipstick urinalysis are eligible for the study.
  • History of intra-abdominal inflammatory process within 6 months prior to screening, including but not limited to peptic ulcer disease, diverticulitis, or colitis.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to screening; or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to screening; or anticipation of need for major surgical procedure, other than potentially curative liver resection, during the study; or non-recovery from side effects of any such procedure.
  • Complete healing from minor surgery (e.g., simple excision, tooth extraction) must have occurred at least 7 days before screening.
  • Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID).
  • The occasional use of NSAIDs for the symptomatic relief of medical conditions such as headache or fever is allowed.
  • Serious infection requiring oral or IV antibiotics and/or hospitalization within 4 weeks prior to screening, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact participant safety.
  • Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study.
  • History of malignancy within 5 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
  • Patients with localized prostate cancer (defined as Stage ≤ pT2c, Gleason score ≤ 7, and prostate-specific antigen (PSA) at prostate cancer diagnosis ≤ 20 ng/mL) treated with curative intent and without PSA recurrence are eligible.
  • Patients with pre-existing low-risk prostate cancer (defined as Stage cT1/T2a, Gleason score ≤ 6, and PSA ≤ 10 ng/mL) who are treatment-naive and undergoing active surveillance are eligible.
  • Patients with malignancies associated with a negligible risk of metastasis or death (e.g., risk of metastasis or death < 5% at 5 years) are eligible provided they meet all of the following criteria:
  • Malignancy treated with expected curative intent (e.g., adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent)
  • No evidence of recurrence or metastasis by follow-up imaging and any disease-specific tumor markers.
  • Active or history of autoimmune disease or immune deficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, granulomatosis with polyangiitis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:
  • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
  • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
  • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
  • Rash must cover < 10% of body surface area.
  • Disease is well controlled at baseline and requires only low-potency topical corticosteroids.
  • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months.
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study.
  • Female participants of childbearing potential must have a negative serum pregnancy test result at screening.
  • Left ventricular ejection fraction (LVEF) < 50% assessed by either transthoracic echocardiogram (TTE) or multiple-gated acquisition (MUGA) scan (TTE preferred test) within 6 months prior to screening.
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
  • History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Prior allogeneic stem cell or solid organ transplantation.
  • Active tuberculosis.

Trial locations and contacts

12 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Ezequiel Matias Mauro, MD, PhD contact

+34 932275400 ext. 9155

mauro@recerca.clinic.cat

Eva Bonfill Vernet contact

+34 932275400 ext. 4198

bonfill@recerca.clinic.cat

12 sites in 1 country

Spain12 sites, 12 recruiting

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, 08916

    Esteban Cugat

    Esteban Cugat

    Recruiting

  • Hospital Universitario de Cruces

    Barakaldo, Vizcaya, 48903

    Mikel Gastaca

    Mikel Gastaca

    Recruiting

  • Hospital Universitari de Bellvitge

    Barcelona, Barcelona, 08907

    Mariona Calvo

    Mariona Calvo

    Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona

    Beatriz Mínguez

    Beatriz Mínguez

    Recruiting

  • Hospital Universitario Reina Sofía

    Córdoba, Cordoba, 14004

    Manuel Rodríguez-Perálvarez

    Manuel Rodríguez-Perálvarez

    Recruiting

  • Hospital Universitari Josep Trueta

    Girona, Girona, 17007

    Margarita Sala

    Margarita Sala

    Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, 28007

    Ana Mª Matilla

    Ana Mª Matilla

    Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, 28034

    José Luis Lledó

    José Luis Lledó

    Recruiting

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, 28040

    Ángela Lamarca

    Ángela Lamarca

    Recruiting

  • Hospital Universitario Virgen de la Victoria

    Puerto de la Torre, Málaga, 29010

    Raul Andrade

    Raul Andrade

    Recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008

    Carlos Lopez

    Carlos Lopez

    Recruiting

  • Hospital Universitario y Politécnico La Fe

    Valencia, Valencia, 46026

    Marina Berenguer

    Marina Berenguer

    Recruiting

Other trials in Spain

About this study

Official title: A Phase II, Randomized, Open-label, National, Multicenter Study Evaluating the Efficacy and Safety of the Combination of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in Hepatocellular Carcinoma (ASPIRE)

Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.

Being tested
Atezolizumab and Bevacizumab
Keywords
resectable HCC with high risk of recurrence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Atezolizumab and BevacizumabDrug

    Participants will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31) until surgery or unacceptable toxicity, whichever occurs first (neoadjuvant therapy).

    The adjuvant therapy with Atezo + Bev will start between 4 and 12 weeks after the resection date, once the participant has fully recovered from the surgery. Participants will receive up to 12 months or 17 cycles of treatment, whichever occurs first, or until disease recurrence or unacceptable toxicity.

Study groups in NCT07018947
Study groupRoleWhat they receive
Atezolizumab and BevacizumabExperimentalParticipants in the atezolizumab plus bevacizumab (Atezo + Bev) arm will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31) until surgery or unacceptable toxicity, whichever occurs first (neoadjuvant therapy). The adjuvant therapy with Atezo + Bev will start between 4 and 12 weeks after the resection date, once the participant has fully recovered from the surgery. Participants will receive up to 12 months or 17 cycles of treatment, whichever occurs first, or until disease recurrence or unacceptable toxicity.
Receives: Drug: Atezolizumab and Bevacizumab
SurvillanceNo interventionIn Arm Survillance, participants will receive standard of care with no neoadjuvant and adjuvant treatment, undergo surgical resection.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recurrence-free survival (RFS)

    Measured by RFS, defined as the time from randomization to the first documented recurrence of disease according to RECIST v1.1 and mRECIST by the investigator's radiology team, or death from any cause (whichever occurs first).

    Measured: From randomization to the first documented recurrence of disease or death from any cause, whichever occurs first, assessed up to 5 years.

Secondary outcomes (13)

  1. Pathological response

    Measured by MPR rate, defined as the proportion of participants with > 70% necrosis of tumor in the tumor bed at the time of surgery, as assessed by central pathological review.

    Measured: Surgery

  2. Pathological response

    Measured by complete pathological response (pCR) rate, defined as the proportion of participants with an absence of residual tumor at the time of surgery, as assessed by central pathological review.

    Measured: Surgery

  3. Overall Survival (OS)

    Measured by OS, defined as the time from randomization to death from any cause.

    Measured: From randomization to death from any cause, assessed up to 5 years.

  4. Efficacy of neoadjuvant with atezolizumab plus bevacizumab treatment combinations

    Measured by Event-free survival (EFS), defined as time from randomization to predefined event, that may include disease progression/toxicity precluding surgery, relapse [ both assessed according to RECIST v1.1 and mRECIST by the investigator's radiology team] or death.

    Measured: From randomization to predefined event or death, whichever came first, assessed up to 5 years.

  5. Efficacy of neoadjuvant with atezolizumab plus bevacizumab treatment combinations

    Measured by objective response rate (ORR), defined as the proportion of participants with a radiological CR or PR prior to surgery, as determined by the investigator according to RECIST v1.1 and HCC mRECIST. Responses will be assessed and determined according to RECIST v1.1 and HCC mRECIST but are not required to be confirmed by subsequent imaging assessments.

    Measured: Pre-Surgery visit

  6. Efficacy of neoadjuvant with atezolizumab plus bevacizumab treatment combinations

    Measured by R0 resection rate (proportion of resected participants obtaining an R0 resection). R0 resection is defined as a microscopically margin-negative resection, in which no tumor (gross or microscopic) remains in the primary tumor bed.

    Measured: Surgery

  7. Safety and tolerability of neoadjuvant + adjuvant atezolizumab and bevacizumab treatment combinations.

    Measured by the incidence, nature, and severity of adverse events, serious adverse events, and immune-related adverse events (severity determined according to NCI CTCAE v5.0).

    Measured: From randomization to last follow-up visit, an averago of 2-5 years.

  8. Surgical feasibility in participants receiving neoadjuvant immunotherapy-based treatment combinations

    Measured by proportion of participants with delayed or canceled surgery (defined as > 28 days from surgical restaging visit), as well as length of surgical delay, duration of surgery, surgical approach and extent of surgery.

    Measured: Surgery

  9. Surgical outcomes in participants receiving neoadjuvant immunotherapy-based treatment combinations

    Measured by proportion of participants with length of hospital stays, intraoperative blood loss, and need for intraoperative blood transfusion.

    Measured: Surgery

  10. Surgical morbidity in participants receiving neoadjuvant immunotherapy-based treatment combinations

    Measured by proportion of participants with length of hospital stays, intraoperative blood loss, and need for intraoperative blood transfusion.

    Measured: Surgery

  11. Surgical mortality in participants receiving neoadjuvant immunotherapy-based treatment combinations

    Measured by proportion of participants with length of hospital stays, intraoperative blood loss, and need for intraoperative blood transfusion.

    Measured: Surgery

  12. Outcomes, morbidity, and mortality in participants receiving neoadjuvant immunotherapy-based treatment combinations.

    Measured by post-operative surgical complication rates according to the Clavien-Dindo surgical classification. Clinically relevant complications are defined as Clavien-Dindo Grade ≥ IIIa.

    Measured: Post-Surgery visit and from visit 8 to the last visit

  13. Mortality in participants receiving neoadjuvant immunotherapy-based treatment combinations

    Measured by post-operative mortality, defined as death within 90 days after surgery.

    Measured: 90 days after the surgery visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jun 2025
  2. Study start2 Jun 2026
  3. Primary completionJun 2031 (estimated)
  4. Study completionJun 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07018947
Sponsor's protocol ID
2025-521459-22-00
Other IDs
2025
Acronym
ASPIRE
Status last verified
Jul 2026
First submitted
27 May 2025
Last updated
8 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Atezolizumab and Bevacizumab in people with Resectable Hepatocellular Carcinoma, run by Fundacion Clinic per a la Recerca Biomédica at 12 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 32 inclusion and 59 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ezequiel Matias Mauro, MD, PhD (+34 932275400 ext. 9155, mauro@recerca.clinic.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recurrence-free survival (RFS) (time frame: From randomization to the first documented recurrence of disease or death from any cause, whichever occurs first, assessed up to 5 years.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07018947.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in